Apyx Medical Q1 revenue $9.4M (-8% YoY), Advanced Energy +6%, net loss narrows to $4.2M

Apyx Medical Corp

Net loss attributable to stockholders $4.2M ($0.10/sh) vs $7.6M ($0.22/sh) prior year; adjusted EBITDA loss $2.4M vs $5.3M.
Advanced Energy revenue up 6% to $7.9M; OEM down 45% to $1.5M. Total revenue $9.4M vs $10.2M.
Reaffirmed FY2025 guidance: total revenue $47.6M-$49.0M, Advanced Energy $39.6M-$41.0M, OEM ~$8.0M.
Planned launch of AYON Body Contouring System in H2 2025 pending FDA clearance; 510(k) submitted Q1 2025.
Renuvion won 2025 NewBeauty Award for 'Best Minimally Invasive Skin Tightener'; Dolores Catania named Chief of Confidence.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.